Novo Nordisk A/S (NYSE:NVO) – Analysts at Jefferies Group issued their Q2 2017 earnings estimates for Novo Nordisk A/S in a report issued on Friday. Jefferies Group analyst J. Holford expects that the company will earn $0.60 per share for the quarter. Jefferies Group also issued estimates for Novo Nordisk A/S’s FY2018 earnings at $2.51 EPS and FY2021 earnings at $3.26 EPS.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.chaffeybreeze.com/2017/07/19/equities-analysts-set-expectations-for-novo-nordisk-ass-q2-2017-earnings-nysenvo.html.
Several other brokerages have also recently commented on NVO. BidaskClub raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, June 15th. Zacks Investment Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $49.00 price objective on the stock in a research note on Wednesday, June 21st. TheStreet upgraded Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research note on Tuesday, May 2nd. Finally, HSBC Holdings plc lowered Novo Nordisk A/S from a “hold” rating to a “reduce” rating in a research note on Friday, April 7th. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $53.00.
Novo Nordisk A/S (NYSE NVO) opened at 43.19 on Monday. The company has a market capitalization of $107.79 billion, a P/E ratio of 18.34 and a beta of 0.63. The firm has a 50-day moving average price of $43.05 and a 200 day moving average price of $38.01. Novo Nordisk A/S has a 12 month low of $30.89 and a 12 month high of $57.41.
A number of hedge funds have recently added to or reduced their stakes in NVO. Proficio Capital Partners LLC raised its stake in Novo Nordisk A/S by 155.6% in the first quarter. Proficio Capital Partners LLC now owns 2,472 shares of the company’s stock valued at $103,000 after buying an additional 1,505 shares in the last quarter. Perigon Wealth Management LLC acquired a new stake in Novo Nordisk A/S during the fourth quarter valued at about $105,000. Tower Research Capital LLC TRC raised its stake in Novo Nordisk A/S by 167.8% in the first quarter. Tower Research Capital LLC TRC now owns 3,061 shares of the company’s stock valued at $105,000 after buying an additional 1,918 shares in the last quarter. Parallel Advisors LLC raised its stake in Novo Nordisk A/S by 120.3% in the first quarter. Parallel Advisors LLC now owns 2,844 shares of the company’s stock valued at $117,000 after buying an additional 1,553 shares in the last quarter. Finally, Advisory Services Network LLC acquired a new stake in Novo Nordisk A/S during the first quarter valued at about $127,000. Hedge funds and other institutional investors own 6.34% of the company’s stock.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Ratings for Novo Nordisk A/S Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Novo Nordisk A/S and related companies with MarketBeat.com’s FREE daily email newsletter.